DALLAS, January 27, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Endometriosis - Pipeline Review, H1 2015" industry research report to its store. This report provides an overview of the Endometriosis's therapeutic pipeline.
The report "Endometriosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects.
Endometriosis is the abnormal growth of cells similar to those that form the inside of the uterus. Endometrial cells in areas outside the uterus are also influenced by hormonal changes and respond in a way that is similar to the cells found inside the uterus. Endometriosis is a common and sometimes incapacitating condition experienced by women of reproductive age. This disease causes chronic pelvic pain and is sometimes associated with infertility. It affects about 5 million American women. There is no cure for endometriosis, but it can be treated in a variety of ways including pain medication, hormonal treatments and surgery. Complete Report is Available @ http://www.rnrmarketresearch.com/endometriosis-pipeline-review-h1-2015-market-report.html .
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies discussed in this Endometriosis Pipeline Review H2 2015 report include AbbVie Inc., Addex Therapeutics Ltd, APAvadis Biotechnologies Srl, Astellas Pharma Inc., Bayer AG, Dongkook Pharmaceutical Co., Ltd., ElexoPharm GmbH, EndoCeutics, Inc., Euroscreen S.A., Evotec AG, Forendo Pharma Oy, GlaxoSmithKline plc, Isifer AB, Kissei Pharmaceutical Co., Ltd., Lipicard Technologies Limited, Neurocrine Biosciences, Inc., Orphagen Pharmaceuticals, Inc., Philogen S.p.A., PregLem SA, Repros Therapeutics Inc., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, ValiRx Plc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269524 . (This is a premium report priced at US$2000 for a single user License.)
Scope of Endometriosis - Pipeline Review, H2 2015 covers: a snapshot of the global therapeutic landscape of Endometriosis; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects; The report summarizes all the dormant and discontinued pipeline projects; A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule typ as well as Latest news and deals relating related to pipeline products.
Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269524 . (This is a premium report priced at US$2000 for a single user License.)
Global Markets Direct report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometriosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Women's Health therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .
RnRMarketResearch.com is a digital library of 500,000+ syndicated market research reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
SOURCE RnR Market Research